MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Johnson and Johnson' source. Thu, 09 Feb 2012 01:31:32 +0100 http://www.medworm.com/index.php?rid=5669453&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FIncreased-Use-of-Computers-Portable-Gadgets-Leading-To-More-Visual-Fatigue-and-Discomfort Jacksonville, FL (January 31, 2012)  – More than 80 percent of American adults own a cell phone and over half (55%) own a desktop or laptop computer[1]. Studies have found that people who spend many hours a day working or playing games on a computer, and/or texting on their cell phones, can suffer from eye discomfort, headaches, and fatigue..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5669453 Tue, 31 Jan 2012 14:12:21 +0100 5669453 http://www.medworm.com/index.php?rid=5669454&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FJohnson-and-Johnson-Joins-Public-and-Private-Partners-in-the-Largest-Coordinated-Action-to-Date-to-Eliminate-or-Control-Neglected-Tropical-Diseases January 30, 2012 - London – Today Johnson & Johnson joined the World Health Organization (WHO), 12 other pharmaceutical companies, the Bill & Melinda Gates Foundation, the U.S. and U.K. governments, the World Bank, and officials from endemic countries in a new, coordinated action to eliminate or control by the end of the decade 10 neglected tropical diseases (NTDs) that affect more than a billion people in the world..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5669454 Sun, 29 Jan 2012 13:04:43 +0100 5669454 http://www.medworm.com/index.php?rid=5631214&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FJanssen-Healthcare-Innovation-Announces-JANSSEN-CONNECTED-CARE-CHALLENGE-to-Spur-Innovation-in-Patient-Care Washington D.C. (January 26, 2012)—Today Janssen Healthcare Innovation , a team within Janssen Research & Development, LLC., (Janssen), announced the Janssen Connected Care Challenge at the Health Care Innovations Summit in Washington, D.C. The Janssen Connected Care Challenge calls for technology solutions to improve the coordination of care for patients as they are being discharged from the hospital.   Janssen Healthcare Innovation will award a total of $250,000 to support further development of the top three ideas that improve healthcare outcomes.&#160..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5631214 Thu, 26 Jan 2012 12:55:37 +0100 5631214 http://www.medworm.com/index.php?rid=5631215&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FAlzheimers-Challenge-2012-Seeking-New-Tools-To-Help-Improve-Alzheimers-Care South San Francisco (January 26, 2012) – Janssen Alzheimer Immunotherapy, together with its collaborator on the Alzheimer’s Immunotherapy Program (AIP), Pfizer Inc. (NYSE: PFE), and the Geoffrey Beene Gives Back® (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5631215 Thu, 26 Jan 2012 12:49:46 +0100 5631215 http://www.medworm.com/index.php?rid=5631216&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FJohnson-and-Johnson-Reports-2011-Fourth-Quarter-and-Full-Year-Results New Brunswick, NJ (January 24, 2012) – Johnson & Johnson today announced sales of $16.3 billion for the fourth quarter of 2011, an increase of 3.9% as compared to the fourth quarter of 2010. Operational sales increased 4.0% and the negative impact of currency was 0.1%. Domestic sales declined 3.4%, while international sales increased 10.2%, reflecting an operational increase of 10.4% and a negative currency impact of 0.2%. Worldwide sales for the full-year 2011 were $65.0 billion, an increase of 5.6% versus 2010. Operational sales increased 2.8% and the positive impact of currency was 2.8%.  Domestic sales declined 1.8%, while international sales increased 12.4%, reflecting operational growth of 7.0% and a positive currency impact of 5.4%..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5631216 Tue, 24 Jan 2012 11:55:27 +0100 5631216 http://www.medworm.com/index.php?rid=5600154&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FJohnson-Johnson-To-Host-Analyst-Meeting-To-Discuss-Fourth-Quarter-And-Full-Year-2011-Financial-Results New Brunswick, NJ (Jan. 17, 2012) - Johnson & Johnson will host an analyst meeting at 8:30 a.m. (Eastern Time) on Tuesday, Jan. 24, to discuss fourth-quarter and full-year 2011 financial results.  The meeting will be hosted by William C. Weldon, Chairman of the Board and Chief Executive Officer;    Dominic J. Caruso, Vice President, Finance and Chief Financial Officer; and Louise Mehrotra, Vice President, Investor Relations..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5600154 Tue, 17 Jan 2012 17:43:38 +0100 5600154 http://www.medworm.com/index.php?rid=5600153&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FJanssen-Research-Development-LLC-Opens-JANSSEN-LABS-at-San-Diego SAN DIEGO, Calif., (January 17, 2012)—Janssen Research & Development, LLC, (Janssen) today opens Janssen Labs at San Diego, a 30,000-square-foot life science innovation center, located within the company’s Janssen West Coast Research Center.  The innovation center provides a capital efficient, flexible lab environment for start-up companies pursuing new technologies and research platforms to advance medical care..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5600153 Tue, 17 Jan 2012 07:35:00 +0100 5600153 http://www.medworm.com/index.php?rid=5600155&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FNeutrogena-Signs-Leading-Mexican-Actress-Recording-Artist-Sandra-Echeverria Los Angeles, CA, (January 13, 2012)– Neutrogena, a worldwide leader in clinically proven, dermatologist-recommended skincare and cosmetics, announced today that leading Mexican actress and recording artist Sandra Echeverria has signed on as its newest U.S. Brand Ambassador.  One of today’s leading Latin stars joins fellow beauty icons Miranda Cosgrove, Jennifer Garner, Vanessa Hudgens (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5600155 Fri, 13 Jan 2012 15:55:44 +0100 5600155 http://www.medworm.com/index.php?rid=5600156&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FFirst-And-Only-Meter-To-Look-For-Patterns-Of-High-And-Low-Blood-Sugar-And-Alert-Diabetes-Patients-Right-On-Screen Milpitas, Calif., (January 9, 2012) – The key to reducing the risk of short and long-term complications associated with diabetes is to minimize high and low blood sugar levels.  But, for the nearly 26 million Americans living with diabetes, this can be a daily challenge.  Now, the new OneTouch® Verio™IQ System with PatternAlert™ Technology helps make it fast and easy to zero in on patterns of highs and lows so patients can take action to prevent them in the future.[1<]  It is the first and only meter[2] to display patterns of highs and lows right on screen with messages such as: “Looks like your blood sugar has been running LOW around this time.”  The system was introduced today by LifeScan, Inc., the leading maker of blood glucose monitoring systems........ Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5600156 Mon, 09 Jan 2012 06:03:33 +0100 5600156 http://www.medworm.com/index.php?rid=5573537&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FJanssen-Therapeutics-Announces-Latest-Recipients-Of-LINCC-Funding-Initiative Titusville, NJ, (January 5th, 2012) – Janssen Therapeutics, Division of Janssen Products, LP, today announced the funding recipients of the Linking In-Need Communities to Care Initiative™ (LINCC). The LINCC Initiative provides charitable contributions to select community-based programs that address barriers to accessing and remaining in HIV/AIDS care in disadvantaged communities.  For more information about the LINCC Initiative, please visit http://www.jtgrant-info.com (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5573537 Thu, 05 Jan 2012 16:36:58 +0100 5573537 http://www.medworm.com/index.php?rid=5573538&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FJohnson-Johnson-Announces-First-Quarter-2012-Quarterly-Dividend New Brunswick, NJ (January 3, 2012) – Johnson & Johnson today announced that its Board of Directors has declared a cash dividend for the first-quarter of 2012 of $0.57 per share on the company’s common stock.  The dividend is payable on March 13, 2012, to shareholders of record at the close of business on Feb. 28, 2012. The ex-dividend date is Feb. 24, 2012..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5573538 Tue, 03 Jan 2012 14:36:30 +0100 5573538 http://www.medworm.com/index.php?rid=5573539&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FJanssen-Research-Development-Submits-Application-toUS-FDA-for-XARELTO-rivaroxaban-to-Reduce-Secondary-Cardiovascular-Events-in-Patients-with-Acute-Coronary-Syndrome Raritan, NJ (December 29th, 2011) – Janssen Research & Development, LLC (JRD) announced today that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of XARELTO® (rivaroxaban), an oral anticoagulant, to reduce the risk of (thrombotic) cardiovascular events in patients with Acute Coronary Syndrome (ACS)..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5573539 Thu, 29 Dec 2011 13:57:10 +0100 5573539 http://www.medworm.com/index.php?rid=5489230&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FJanssen-Biotech-Inc-Announces-Collaborative-Development-And-Worldwide-License-Agreement-For-Investigational-Anti-Cancer-Drug-PCI-32765 HORSHAM, PA, (December 8, 2011) – Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE:JNJ), announced today that it has executed an agreement with Pharmacyclics, Inc. (Nasdaq: PCYC) to jointly develop and market the anti-cancer compound, PCI-32765.  A number of Phase 1 and 2 studies with PCI-32765 are ongoing across a panel of B-cell malignancy disorders, including chronic lymphocytic leukemia, mantle cell lymphoma, and diffuse large B-cell lymphoma.  Interim data were reported at the 2011 American Society of Clinical Oncology Annual Meeting and oral presentations on two separate Phase 2 studies will be presented at the upcoming American Society of Hematology Meeting in December, along with several other poster presentations..... (S... Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5489230 Thu, 08 Dec 2011 09:33:05 +0100 5489230 http://www.medworm.com/index.php?rid=5489231&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FFirst-Patient-Enrolled-In-Therakos-Phase-Two-Study-For-Treatment-Of-Graft-Versus-Host-Disease RARITAN, NJ (December 6, 2011) – Therakos, Inc., a pioneer in the innovative treatment of extracorporeal photopheresis (ECP) for immune modulation therapy, today announced that the first patient has been enrolled in its Phase IIb clinical study evaluating the use of the company’s photopheresis technology in the treatment of patients with moderate-to-severe chronic Graft-versus-Host Disease (GvHD). An estimated 15,000 new patients worldwide are diagnosed every year with chronic GvHD, a life threatening condition occurring when a donor’s transplanted stem cells attack the recipient’s body.[1],[2..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5489231 Wed, 07 Dec 2011 11:10:10 +0100 5489231 http://www.medworm.com/index.php?rid=5470685&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FCasey-Abrams-Announces-Winners-Of-Inflammatory-Bowel-Disease-Awareness-Campaign-After-A-National-Vote Horsham, Pa., (December 2, 2011) – The winners of IBD Icons (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5470685 Fri, 02 Dec 2011 16:46:57 +0100 5470685 http://www.medworm.com/index.php?rid=5470686&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FEDURANT-Rilpivirine-Approved-In-Europe-For-Treatment-Naive-Adults-With-HIV-1-Infection-With-A-Baseline-Viral-Load-100-000-HIV-1-RNA-Copies-mL Beerse, Belgium,  (November 28, 2011) (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5470686 Mon, 28 Nov 2011 08:09:23 +0100 5470686 http://www.medworm.com/index.php?rid=5470687&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FJohnson-and-Johnson-to-Participate-in-the-Piper-Jaffray-23-Annual-Health-Care-Conference New Brunswick, NJ (Nov. 28, 2011) -- Johnson & Johnson will participate in the Piper Jaffray 23rd Annual Health Care Conference on Tuesday, Nov. 29th at The New York Palace, New York, NY.  Gary Pruden, Company Group Chairman, Ethicon will present in a session scheduled at 8:00 a.m. (Eastern Time)..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5470687 Mon, 28 Nov 2011 08:07:24 +0100 5470687 http://www.medworm.com/index.php?rid=5470688&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FJohnson-and-Johnson-to-Participate-in-the-Piper-Jaffray-23rd-Annual-Health-Care-Conference New Brunswick, NJ (Nov. 22, 2011) -- Johnson & Johnson will participate in the Piper Jaffray 23rd (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5470688 Tue, 22 Nov 2011 15:49:29 +0100 5470688 http://www.medworm.com/index.php?rid=5402250&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FLandmark-Study-Shows-that-Adding-Rivaroxaban-to-Standard-Antiplatelet-Therapy-Significantly-Reduced-Secondary-Cardiovascular-Events-in-Patients-with-Acute-Coronary-Syndrome Orlando, FL (November 13, 2011) — Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced today that adding oral rivaroxaban to standard antiplatelet therapy significantly reduced the composite primary efficacy endpoint of cardiovascular-related deaths, heart attacks or strokes in patients with acute coronary syndrome (ACS) compared to those receiving standard therapy alone. Results from the pivotal Phase 3 ATLAS ACS 2 TIMI 51 trial presented today at the American Heart Association Scientific Sessions and published in the New England Journal of Medicine also showed that rivaroxaban significantly increased rates of major bleeding, but did not create an excess risk of fatal bleeding over standard therapy alone..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5402250 Sun, 13 Nov 2011 13:00:00 +0100 5402250 http://www.medworm.com/index.php?rid=5402251&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FJanssen-Pharmaceutical-Companies-Launch-Healthy-Minds-Initiative-to-Spur-Neuroscience-Collaboration-and-Support-Millions-Suffering-from-Brain-Disorders Titusville, NJ (November 10, 2011) (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5402251 Fri, 11 Nov 2011 13:43:44 +0100 5402251 http://www.medworm.com/index.php?rid=5402252&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FEthicon-Endo-Surgery-Receives-510-K-Clearance-For-New-ENSEAL-G2-Curved-and-Straight-Tissue-Sealers-Line Cincinnati, OH (November 10, 2011) –Ethicon Endo-Surgery, Inc. (EES) today announces U.S. FDA 510(k) clearance of their innovative ENSEAL® G2 Curved and Straight Tissue Sealers line to expand surgeons’ options for achieving strong vessel seals while remaining gentle on tissue in both open and minimally invasive surgery .  This line of eight new tissue sealer devices include four shaft lengths and options for curved and straight jaws to meet each unique surgical need.  Along with ENSEAL® G2 Super Jaw, the ENSEAL® G2 Tissue Sealer line provides surgeons with the broadest portfolio of advanced bipolar tissue sealers to provide more options in both open and minimally invasive surgical procedures such as colorectal, gynecological and general surgery. The ENSEAL® G2 Tissue Seal... Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5402252 Thu, 10 Nov 2011 06:43:03 +0100 5402252 http://www.medworm.com/index.php?rid=5402253&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FIs-Your-Mouth-As-Clean-As-You-Think-Celebrity-Kristin-Chenoweth-And-The-Makers-Of-Listerine-Antiseptic-Inspire-Americans-To-Redefine-Clean-When-It-Comes-To-Oral-Care MORRIS PLAINS, NJ (November 9, 2011)  –  (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5402253 Wed, 09 Nov 2011 14:32:08 +0100 5402253 http://www.medworm.com/index.php?rid=5402254&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FNew-sirukumab-CNTO-136-Phase-2-Data-Show-Efficacy-of-Interleukin-6-Inhibitor-across-Multiple-Dose-Regimens-in-Treatment-of-Rheumatoid-Arthritis Chicago, IL (November 7, 2011) – Results from Part B of a two-part Phase 2 study of sirukumab (CNTO 136), a subcutaneously administered human antibody directed against the cytokine interleukin (IL)-6, showed that patients with active rheumatoid arthritis (RA) receiving the monoclonal antibody demonstrated substantial improvement in signs and symptoms and inflammation.  Findings from the proof-of-concept, dose-finding study of patients with active RA despite methotrexate therapy will be presented at the 2011 American College of Rheumatology Annual Scientific Meeting and follow positive Part A study results previously presented (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5402254 Mon, 07 Nov 2011 14:35:43 +0100 5402254 http://www.medworm.com/index.php?rid=5402255&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FINCIVO-telaprevir-Demonstrates-Efficacy-and-Increased-Cure-Rates-among-Cirrhotic-Patients-with-Genotype-1-Chronic-HCV-Compared-to-Standard-of-Care San Francisco, CA (November 5th, 2011) (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5402255 Sun, 06 Nov 2011 16:24:05 +0100 5402255 http://www.medworm.com/index.php?rid=5402256&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FTibotec-To-Present-Final-Safety-And-Efficacy-Results-From-Phase-2b-PILLAR-Study-Of-Once-Daily-TMC435-In-Late-Breaker-At-AASLD San Francisco, CA. (November 5, 2011) – Tibotec Pharmaceuticals (Tibotec), one of the Janssen (Janssen) Pharmaceutical Companies, today will present results of the final analysis of PILLAR, a phase 2b study of the investigational hepatitis C virus (HCV) NS3/4A protease inhibitor TMC435 in treatment-naïve patients with chronic genotype 1 HCV, as part of a late-breaker oral presentation at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco, CA, USA..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5402256 Sat, 05 Nov 2011 08:42:03 +0100 5402256 http://www.medworm.com/index.php?rid=5402257&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FSterilMed-Names-Mike-Gustafson-Company-President Maple Grove, MN (November 4, 2011) –SterilMed, Inc. (SterilMed), a leader in the reprocessing and remanufacturing of single use medical devices, today announced the appointment of Mike Gustafson as Company President.  Gustafson will succeed Brian Sullivan, who intends to retire from the company following a transition period.&#160..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5402257 Fri, 04 Nov 2011 09:39:30 +0100 5402257 http://www.medworm.com/index.php?rid=5402258&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FEthicon-Endo-Surgery-Completes-Acquisition-of-SterilMed Cincinnati, OH (November 4, 2011) – Ethicon Endo-Surgery, Inc. (EES), a global leader in the development of innovative medical devices for minimally invasive and open surgical procedures, today announced the closing of the transaction to acquire SterilMed, Inc. (SterilMed), a leader in the reprocessing and remanufacturing of single-use medical devices in the United States..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5402258 Fri, 04 Nov 2011 09:33:43 +0100 5402258 http://www.medworm.com/index.php?rid=5402259&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FFDA-Approves-XARELTO-Rivaroxaban-To-Reduce-The-Risk-Of-Stroke-And-Systemic-Embolism-In-Patients-With-Nonvalvular-Atrial-Fibrillation RARITAN, NJ, (November 4, 2011) (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5402259 Fri, 04 Nov 2011 06:38:44 +0100 5402259 http://www.medworm.com/index.php?rid=5402260&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FSteering-Drivers-In-The-Right-Direction-Healthy-Vision-With-Dr-Val-Jones-Radio-Show-Offers-Information-Advice-About-Driving-In-The-Dark JACKSONVILLE, Fla. (November 1, 2011)  –   When you are behind the wheel of a car, your eyes are constantly on the move – looking at vehicles ahead and to the side, reading road traffic signs, checking your rear view mirrors, and shifting your gaze inside and outside your vehicle in order to check the speedometer, look at your global navigation system, or change a radio station..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5402260 Tue, 01 Nov 2011 13:20:12 +0100 5402260 http://www.medworm.com/index.php?rid=5402261&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FSupplemental-New-Drug-Application-Submitted-To-FDA-For-NUCYNTA-ER-Tapentadol-Extended-Release-Tablets-For-Diabetic-Peripheral-Neuropathic-Pain TITUSVILLE, N.J., (October. 31, 2011) -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced today that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for NUCYNTA® ER (tapentadol) extended-release tablets, an oral analgesic, for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults. The FDA approved NUCYNTA® ER on August 25, 2011, for the management of moderate to severe chronic pain in adults when a continuous, around-the-clock opioid analgesic is needed for an extended period of time..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5402261 Mon, 31 Oct 2011 13:46:50 +0100 5402261 http://www.medworm.com/index.php?rid=5339152&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FSTELARA-Ustekinumab-Is-Effective-Well-Tolerated-And-Improves-Quality-Of-Life-In-Patients-With-Moderate-To-Severe-Plaque-Psoriasis-Inadequately-Responsive-To-Methotrexate Beerse, Belgium (October 21, 2011) – New findings from the TRANSIT study were presented today at the 20th (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5339152 Fri, 21 Oct 2011 14:37:03 +0100 5339152 http://www.medworm.com/index.php?rid=5339153&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FFDA-Approves-Label-Update-for-PREZISTA-to-Include-192-Week-Data-in-HIV-1-Infected-Adult-Patients-Starting-Treatment Titusville, NJ (Oct. 21, 2011) -- Janssen Therapeutics, Division of Janssen Products, LP, announced today that the U.S. Food and Drug Administration (FDA) has approved a label update for PREZISTA® (darunavir) tablets to include 192-week data from the ARTEMIS study.  ARTEMIS evaluated the efficacy and safety of PREZISTA with ritonavir (r) vs. lopinavir/r in combination with other antiretrovirals (ARVs) for the treatment of human immunodeficiency virus (HIV-1) in treatment-naive patients..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5339153 Fri, 21 Oct 2011 14:00:06 +0100 5339153 http://www.medworm.com/index.php?rid=5339154&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FEthicon-Endo-Surgery-Showcases-Innovative-Learning%2520Journey-Procedure-Focused-Educational-Presentations-and-Key-Product-Innovations-at-the-ACS-Conference Cincinnati, OH (October 21, 2011) – As part of its nearly 20-year commitment to providing surgeons, residents, nurses and other healthcare providers the information and training they need to keep up with rapid advancements in surgical procedures and technology, Ethicon Endo-Surgery (EES) today introduced a new interactive web resource, EESeducation.com, at the 97th (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5339154 Fri, 21 Oct 2011 13:03:18 +0100 5339154 http://www.medworm.com/index.php?rid=5339155&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FJohnson-and-Johnson-Announces-Fourth-Quarter-2011-Quarterly-Dividend New Brunswick, NJ (October 21, 2011) – Johnson & Johnson today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2011 of $0.57 per share on the company’s common stock.  The dividend is payable on Dec. 13, 2011, to shareholders of record at the close of business on Nov. 29, 2011. The ex-dividend date is Nov. 25, 2011..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5339155 Fri, 21 Oct 2011 12:20:37 +0100 5339155 http://www.medworm.com/index.php?rid=5339156&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FJanssen-Data-Focus-On-Tolerability-and-Treatment-Simplification-in-HIV-Compounds Belgrade, Serbia, (October 13, 2011) – Tibotec Pharmaceuticals, one of the Janssen Pharmaceutical Companies (Janssen), presented new data across their HIV portfolio at the 13th annual European Aids Conference (EACS) demonstrating the company’s commitment to exploring and developing new HIV treatment options which could help improve treatment for patients at every stage of the disease. Key highlights include..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5339156 Thu, 20 Oct 2011 13:38:48 +0100 5339156 http://www.medworm.com/index.php?rid=5339157&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FNew-Survey-Reveals-Americans-Want-Better-Access-To-and-Understanding-of-Blood-Test-Results Raritan, NJ (October 19, 2011) — Ortho Clinical Diagnostics (OCD), in partnership with the National Association of Chronic Disease Directors (NACDD), today unveiled new consumer survey results and a report revealing the state of blood test health literacy in the United States with strategies to support much-needed patient education and empowerment. The first step: ensuring patient access to and understanding of blood test results, a critical component to maintaining health and wellness.  The campaign kicks off during National Health Literacy Month, an awareness effort founded in 1999 to promote the importance of understandable health information.&#160..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5339157 Wed, 19 Oct 2011 12:57:48 +0100 5339157 http://www.medworm.com/index.php?rid=5339158&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FJohnson-and-Johnson-Reports-2011-Third-Quarter-Results New Brunswick, NJ (October 18, 2011) – Johnson & Johnson today announced sales of $16.0 billion for the third quarter of 2011, an increase of 6.8% as compared to the third quarter of 2010.  Operational results increased 2.6% and the positive impact of currency was 4.2%.  Domestic sales declined 3.7%.  International sales increased 16.4%, reflecting operational growth of 8.3% and a positive currency impact of 8.1%..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5339158 Tue, 18 Oct 2011 11:01:34 +0100 5339158 http://www.medworm.com/index.php?rid=5516878&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FASP-Recognizes-25th-Annual-International-Infection-Prevention-Week-in-Quest-to-Protect-Lives-against-Infection Irvine, CA (October 17, 2011): Advanced Sterilization Products (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5516878 Mon, 17 Oct 2011 06:50:20 +0100 5516878 http://www.medworm.com/index.php?rid=5317605&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FNeutrogena-Wave-for-Change-Donates-Over-a-Quarter-of-Million-Dollars-to-Benefit-Disaster-Relief-Education-and-Environmental-Charities Los Angeles, CA (September 12th (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5317605 Wed, 12 Oct 2011 09:36:30 +0100 5317605 http://www.medworm.com/index.php?rid=5317606&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FBabyCenter-Launches-My-Baby-Today-App-for-iPhone-and-iPod-touch San Francisco, CA (October 12, 2011) –  (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5317606 Wed, 12 Oct 2011 05:52:54 +0100 5317606 http://www.medworm.com/index.php?rid=5317607&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FJohnson-Johnson-To-Host-Analyst-Conference-Call-On-Third-Quarter-Results New Brunswick, NJ (October 11, 2011) - Johnson & Johnson will host a conference call for financial analysts at 8:30 a.m. (Eastern Time) on Tuesday, October 18, 2011, to review third-quarter results.  Dominic Caruso, Vice President, Finance and Chief Financial Officer, and Louise Mehrotra, Vice President, Investor Relations, will host the call..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5317607 Tue, 11 Oct 2011 13:31:08 +0100 5317607 http://www.medworm.com/index.php?rid=5288411&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FScios-Inc-Announces-Agreement-with-Department-of-Justice-Regarding-NATRECOR Raritan, NJ (October 5, 2011) – Today Scios Inc. announced an agreement with the United States Department of Justice to resolve allegations of misbranding of NATRECOR® (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5288411 Wed, 05 Oct 2011 13:05:01 +0100 5288411 http://www.medworm.com/index.php?rid=5288412&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FKeep-Your-Eyes-On-the-Ball-Healthy-Vision-With-Dr-Val-Jones-Radio-Show-Highlights-the-Relationship-between-Vision-and-Performance-in-Sports Jacksonville, FL (October 4, 2011) – Vision, just like speed and strength, is an important component in how well you play your sport.  But, there is much more to vision than just seeing clearly. On the new edition of Healthy VisionTM (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5288412 Tue, 04 Oct 2011 13:07:40 +0100 5288412 http://www.medworm.com/index.php?rid=5263785&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FCasey-Abrams-Announces-Finalists-in-National-Inflammatory-Bowel-Disease-Awareness-Campaign-and-Calls-on-America-to-Vote Horsham PA, (September 29, 2011) – Season 10 American Idol (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5263785 Thu, 29 Sep 2011 12:59:41 +0100 5263785 http://www.medworm.com/index.php?rid=5263787&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FSTELARA-Awarded-2011-Prix-Galien-USA-in-Best-Biotechnology-Product-Category Horsham, PA (September 28, 2011) – Janssen Biotech, Inc. announced today that STELARA® (ustekinumab) has been awarded the prestigious 2011 Prix Galien USA Award in the category of Best Biotechnology Product.  The Prix Galien USA (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5263787 Wed, 28 Sep 2011 14:24:40 +0100 5263787 http://www.medworm.com/index.php?rid=5263788&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FEthicon-Endo-Surgery-to-Acquire-SterilMed Cincinnati, OH (September 28, 2011) – Ethicon Endo-Surgery, Inc. (EES), a global leader in the development of innovative medical devices for minimally invasive and open surgical procedures, today announced a definitive agreement to acquire privately-held SterilMed, Inc. (SterilMed), a leader in the reprocessing and remanufacturing of medical devices in the United States. Financial terms of the agreement are not being disclosed..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5263788 Wed, 28 Sep 2011 12:08:48 +0100 5263788 http://www.medworm.com/index.php?rid=5263786&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FMcNeil-PPC-Inc-Acquires-Full-Ownership-Of-The-Johnson-Johnson-Merck-Consumer-Pharmaceuticals-Co-Joint-Venture FORT WASHINGTON, PA, (September 28, 2011) – McNEIL-PPC, Inc. and its affiliate McNeil MMP, LLC (McNEIL) announced today that they have completed the acquisition of full ownership of the Johnson & Johnson•Merck Consumer Pharmaceuticals Co. joint venture in the United States from Merck Sharp & Dohme Corp. (Merck). The joint venture will be renamed McNeil Consumer Pharmaceuticals Co. and will continue to market products under the PEPCID®, MYLANTA®, and MYLICON® brands..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5263786 Wed, 28 Sep 2011 08:38:43 +0100 5263786 http://www.medworm.com/index.php?rid=5263790&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FHealth-Canada-Approves-Expanded-Indication-For-SIMPONI-To%2520Include-Inhibition-Of-Structural-Damage-In-The-Treatment-Of-Moderately-To-Severely-Active-Rheumatoid-Arthritis TORONTO, Canada (September 22, 2011) – Janssen Inc. announced today that Health Canada has expanded the approved indication for SIMPONI® (golimumab), in combination with methotrexate, to include the inhibition of progression of structural damage in adult patients with moderately to severely active rheumatoid arthritis who had not previously been treated with methotrexate. Health Canada also approved an expanded indication in the improvement of physical function in adult patients with moderately to severely active rheumatoid arthritis.[1]  Rheumatoid arthritis is an inflammatory condition that if left untreated, can lead to permanent damage such as joint deformity and disability.[2..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5263790 Fri, 23 Sep 2011 16:20:17 +0100 5263790 http://www.medworm.com/index.php?rid=5263791&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FEDURANT-Rilpivirine-Receives-Positive-Opinion-from-the-Committee-for-Medicinal-Products-for-Human-Use-CHMP-For-Use-in-Treatment-Naive-Adults-with-HIV-1 Titusville, NJ (September 23, 2011) – (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5263791 Fri, 23 Sep 2011 15:47:34 +0100 5263791 http://www.medworm.com/index.php?rid=5263789&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FREMICADE-Receives-FDA-Approval-as-First-Biologic-Treatment-for-Pediatric-Ulcerative-Colitis Horsham, PA (September 23, 2011) – Janssen Biotech, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved REMICADE® (infliximab) for the treatment of moderately to severely active ulcerative colitis (UC) in pediatric patients who have had an inadequate response to conventional therapy.  This marks the 16th (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5263789 Fri, 23 Sep 2011 09:58:02 +0100 5263789 http://www.medworm.com/index.php?rid=5241302&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FINCIVO-Telaprevir-Approved-In-Europe-Offering-Higher-Cure-Rates-for-Genotype-1-Chronic-Hepatitis-C-Compared-To-Standard-Treatment Beerse, Belgium, (September 20, 2011) (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5241302 Tue, 20 Sep 2011 06:22:56 +0100 5241302 http://www.medworm.com/index.php?rid=5241303&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FJohnson-and-Johnson-Makes-Strong-Progress-in-First-Year-of-Initiative-to-Improve-Health-of-Millions-of-Women-and-Children-in-the-Developing-World New Brunswick, NJ (September 20, 2011) – Johnson & Johnson today announced important progress made in the inaugural year of the Company’s comprehensive effort designed to improve the health of as many as 120 million women and children each year in developing countries by 2015..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5241303 Tue, 20 Sep 2011 06:15:54 +0100 5241303 http://www.medworm.com/index.php?rid=5241304&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FActress-Jane-Kaczmarek-Teams-Up-With-DePuy-Orthopaedics-to-Launch-Osteoarthritis-Awareness-and-Education-Program Warsaw, IN (Sept. 15, 2011) – Motivated by her behind-the-scenes struggle with severe hip pain, Emmy®-nominated actress and bilateral hip replacement patient Jane Kaczmarek is joining forces with DePuy Orthopaedics, Inc. (DePuy) to launch the Anatomy of Movement Experience (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5241304 Thu, 15 Sep 2011 12:18:37 +0100 5241304 http://www.medworm.com/index.php?rid=5241306&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FNew-Survey-Shows-Moderate-To-Severe-Acute-Pain-Is-Widely-Undertreated-Especially-Among-Older-Adults Raritan, NJ (September 14, 2011) – A new survey shows almost half (44%) of U.S. patients in outpatient settings received potentially inadequate relief of moderate-to-severe acute pain.   (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5241306 Wed, 14 Sep 2011 15:02:11 +0100 5241306 http://www.medworm.com/index.php?rid=5241307&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FJohnson-Johnson-Symposium-Honors-2011-Recipient-Of-The-Dr-Paul-Janssen-Award-For-Biomedical-Research New York, NY (September 14, 2011) – (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5241307 Wed, 14 Sep 2011 13:50:23 +0100 5241307 http://www.medworm.com/index.php?rid=5241308&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FLifeScan-Launches-ONETOUCH-SelectSimple-Blood-Glucose-Monitor-With-Audio-Alerts Mumbai, India (September 5, 2011) ― LifeScan, a Johnson & Johnson company launched a breakthrough new blood glucose monitoring device specifically designed to make self-monitoring simple and meaningful for the millions of Indians with diabetes.  Called ONETOUCH® SelectSimple™, (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5241308 Wed, 14 Sep 2011 13:33:42 +0100 5241308 http://www.medworm.com/index.php?rid=5241305&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F24-Week-Incivo-Telaprevir-Based-Regimen-Effective-For-Majority-Of-Previously-Untreated-Genotype-1-Chronic-HCV-Patients Beerse, Belgium (September 15, 2011) – Data from ILLUMINATE, a Phase 3 clinical trial investigating response guided therapy with INCIVO® (telaprevir) in combination with peginterferon and ribavirin (PR), in previously untreated patients with genotype-1 chronic hepatitis C (HCV), will be published today in the New England Journal of Medicine (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5241305 Wed, 14 Sep 2011 09:41:10 +0100 5241305 http://www.medworm.com/index.php?rid=5241309&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FNew-Video-Series-Explores-How-People-Living-With-HIV-Have-Overcome-Emotional-Barriers-To-Help-Newly-Diagnosed-In-Their-Own-Journeys TITUSVILLE, N.J., (September 12th 2011) – Chad says his HIV diagnosis in 2009 was the last in a series of life events that left him without hope. He remembers feeling as though he had lost everything, and then lost his health as well.  One way Chad says he emerged from this dark time was by educating himself about the disease and starting to reach out for support. There are still days when he admits he grieves about the past, but Chad now says he feels he is able to accept and move beyond that pain with help from the people in his life who listen to him without judgment.  &#160..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5241309 Mon, 12 Sep 2011 15:39:42 +0100 5241309 http://www.medworm.com/index.php?rid=5516879&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FFDA-Issues-Complete-Response-Letter-To-Janssen-Biotech-Inc-for-Simponi-Supplemental-Biologics-License-Application Horsham, PA (September 9, 2011) – Janssen Biotech, Inc. announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response letter for the SIMPONI® (golimumab) supplemental Biologics License Application (sBLA) seeking an expanded label in the treatment of active psoriatic arthritis.  The application, filed in November 2010, included data from a Phase 3 trial evaluating the effect of SIMPONI® in inhibiting the progression of structural damage and maintaining improvement in signs and symptoms and physical function in the treatment of patients with active psoriatic arthritis.&#160..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5516879 Fri, 09 Sep 2011 05:46:49 +0100 5516879 http://www.medworm.com/index.php?rid=5241310&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FFDA-Issues-Complete-Response-Letter-To-Janssen-Biotech-Inc-for-Simponi-Supplemental-Biologics-License-Application Horsham, PA (September 9, 2011) – Janssen Biotech, Inc. announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response letter for the SIMPONI® (golimumab) supplemental Biologics License Application (sBLA) seeking an expanded label in the treatment of active psoriatic arthritis.  The application, filed in November 2010, included data from a Phase 3 trial evaluating the effect of SIMPONI® in inhibiting the progression of structural damage and maintaining improvement in signs and symptoms and physical function in the treatment of patients with active psoriatic arthritis.&#160..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5241310 Fri, 09 Sep 2011 05:46:49 +0100 5241310 http://www.medworm.com/index.php?rid=5241311&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FFDA-Advisory-Committee-Recommends-Approval-of-Oral-Anticoagulant-Rivaroxaban-for-the-Prevention-of-Stroke-and-Systemic-Embolism-in-Patients-with-Non-Valvular-Atrial-Fibrillation Raritan, NJ (September 8, 2011) — Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD) announced today that the U.S. Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee recommended approval of rivaroxaban, a novel, once-daily, oral anticoagulant, for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF). The committee voted 9-2 in favor of rivaroxaban in patients with AF who are at risk of stroke and systemic embolism..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5241311 Thu, 08 Sep 2011 10:01:59 +0100 5241311 http://www.medworm.com/index.php?rid=5241312&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FZytiga-Approved-In-The-European-Union-For-Metastatic-Castration-Resistant-Prostate-Cancer Beerse, Belgium, (September 7th, 2011) -- Janssen-Cilag International NV announced today that, after an accelerated regulatory review process by the European Medicines Agency (EMA) and following a positive CHMP opinion on the 22 July 2011, the European Commission has approved the marketing authorisation for ZYTIGA® (abiraterone acetate), a novel, once-daily, oral, androgen biosynthesis inhibitor. Abiraterone acetate is approved, in combination with prednisone or prednisolone, for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.[1..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5241312 Wed, 07 Sep 2011 13:39:11 +0100 5241312 http://www.medworm.com/index.php?rid=5241313&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FActress-Meaghan-Martin-And-Acuvue-Brand-Contact-Lenses-Offer-A-Behind%2520-The-Scenes-Look-Into-Fashion-Week Jacksonville, FL (September 7, 2011) – Fashion Week has descended upon New York City and 1-DAY ACUVUE® MOIST® Brand Contact Lenses gives everyone the opportunity to see it through the eyes of all-American actress Meaghan Martin and to participate in style icon Robert Verdi’s annual Luxe Lab Twitter Party..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5241313 Wed, 07 Sep 2011 11:44:27 +0100 5241313 http://www.medworm.com/index.php?rid=5241314&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FJohnson-Johnson-To-Participate-In-Morgan-Stanley-Global-Health-Care-Conference New Brunswick, NJ (September 6, 2011) -- Johnson & Johnson (NYSE: JNJ) will participate in the Morgan Stanley Global Health Care Conference Tuesday, September 13th (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5241314 Tue, 06 Sep 2011 06:34:01 +0100 5241314 http://www.medworm.com/index.php?rid=5186705&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FYoung-Patients-To-Benefit-From-Health-Canada-Approval-Of-Remicade-For-Treatment-Of-Pediatric-Ulcerative-Colitis Toranto, Canada (September 1, 2011) – Young Canadians living with the debilitating inflammatory bowel disease ulcerative colitis (UC) will now have access to a new treatment option with Health Canada’s approval of REMICADE® (infliximab) for use in pediatric patients (age six to 17 years). REMICADE® has been approved for the treatment of UC in adults in Canada since 2006. &#160..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5186705 Thu, 01 Sep 2011 06:42:54 +0100 5186705 http://www.medworm.com/index.php?rid=5186706&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FHealthy-Vision-With-Dr-Val-Jones-Radio-Show-Highlights-the-Importance-of-Good-Vision-to-Childrens-Performance-in-School-Sports-and-Life Jacksonville, FL (August 31, 2011) – As millions of children head back to the classroom, parents are looking for every opportunity to help them be successful in school and in life. On the new edition of Healthy Vision™ with Dr. Val Jones (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5186706 Wed, 31 Aug 2011 13:07:29 +0100 5186706 http://www.medworm.com/index.php?rid=5165226&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FNUCYNTA-ER-Tapentadol-Extended-Release-Tablets-Receives-FDA-Approval-For-The-Management-Of-Moderate-To-Severe-Chronic-Pain Raritan, N.J., August 26, 2011 -- (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5165226 Fri, 26 Aug 2011 13:38:56 +0100 5165226 http://www.medworm.com/index.php?rid=5149526&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FDepuy-Orthopaedics-Receives-FDA-510-K-Clearance-For-Trumatch-Personalized-Solutions WARSAW, IN – Aug. 19, 2011 – (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5149526 Fri, 19 Aug 2011 05:25:36 +0100 5149526 http://www.medworm.com/index.php?rid=5149527&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FJanssen-Pharmaceuticals-Inc-Launches-Online-Tools-On-PrescribeResponsibly-com Raritan, NJ (August 16, 2011) – To assist healthcare professionals in managing their patients’ pain, Janssen Pharmaceuticals, Inc. (JPI) today launched several new resources and tools on PrescribeResponsibly.com (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5149527 Tue, 16 Aug 2011 05:31:49 +0100 5149527 http://www.medworm.com/index.php?rid=5516880&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FJohnson-Johnson-Pharmaceutical-Research-Development-Scientists-Uncover-Previously-Unknown-Role-For-Class-Of-Molecules San Diego, CA (August 4, 2011) – Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced today the publication of research that uncovered a previously unknown role for a class of molecules that could lead to future advances in immunologic medicine.  The findings show a definitive link between EBI2, a G-protein-coupled receptor that controls B-cell migration, and some unexpected immunological effects of certain oxysterols.  Co-authored by the company’s neuroscience and immunology discovery teams, the results of the initiative were published in a Letter in the July 28, 2011 issue of NATURE, “Oxysterols direct B-cell migration through EBI2.” (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5516880 Thu, 04 Aug 2011 08:34:10 +0100 5516880 http://www.medworm.com/index.php?rid=5516881&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FCiti-Teams-Up-With-Babycenter-To-Reach-Moms-During-The-Moments-That-Matter San Francisco, CA and New York, NY—August 3, 2011— (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5516881 Wed, 03 Aug 2011 16:21:54 +0100 5516881 http://www.medworm.com/index.php?rid=5516882&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FBabyCenter-Study-Reveals-Weak-Economys-Effect-on-the-Family (San Francisco) – August 2, 2011 – (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5516882 Wed, 03 Aug 2011 16:11:34 +0100 5516882 http://www.medworm.com/index.php?rid=5516883&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FCelebrity-Chef%2520Sam-Talbot-Joins-Life%2520First-Diabetes-Awareness-Campaign Milpitas, California (August 2, 2011) -- Celebrity chef Sam Talbot, who was diagnosed with type 1 diabetes at age 12, has joined the “Life First™” (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5516883 Wed, 03 Aug 2011 13:18:01 +0100 5516883 http://www.medworm.com/index.php?rid=5082327&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FStigma-Remains-a-Significant-Barrier-to-Routine-HIV-Testing-by-African-American-Physicians-Survey-Finds Titusville, NJ (August. 1, 2011) -- Social stigma is the largest barrier to routine HIV testing by African-American frontline care physicians, according to a survey commissioned by Janssen Therapeutics, Division of Janssen Products, LP, in collaboration with the National Medical Association (NMA).(1) Despite the belief by most physicians surveyed (93 percent) that HIV is either very serious or a crisis in the African-American community, findings suggested that only one-third of all patients in these physicians' practices were tested within the past year..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5082327 Mon, 01 Aug 2011 16:46:40 +0100 5082327 http://www.medworm.com/index.php?rid=5516884&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FZytiga-Abiraterone-Acetate-Receives-Health-Canada-Approval-For-Treatment-Of-Metastatic-Prostate-Cancer Toronto, ON (July 28, 2011) – Janssen Inc. announced today that after a priority review, Health Canada has approved ZYTIGA™ (abiraterone acetate), an oral medication for the treatment of men with metastatic prostate cancer. ZYTIGA™ is indicated with prednisone for the treatment of men with metastatic prostate cancer (castration-resistant prostate cancer) who have received prior chemotherapy containing docetaxel. (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5516884 Thu, 28 Jul 2011 13:45:16 +0100 5516884 http://www.medworm.com/index.php?rid=5516885&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FPeople-With-Diabetes-Endure-Swim-Across-English-Channel-To-Raise-Money-For-JDRF HIGH WYCOMBE, July 21, 2011 – Six swimmers will congregate along the Dover coastline today, to participate in a 17-hour relay swim across the English Channel to France.  The relay event, sponsored by Animas®, aims to raise money for the Juvenile Diabetes Research Foundation (JDRF) and celebrate people with diabetes performing at their best. To date, the relay team has already raised more than £1,700 for the JDRF, through their ‘Just Giving’ website at: www.justgiving.com/animas-swimmers (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5516885 Thu, 28 Jul 2011 13:16:44 +0100 5516885 http://www.medworm.com/index.php?rid=5072715&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FMcneil-Consumer-Healthcare-Announces-Plans-For-New-Dosing-Instructions-For-Tylenol-Products Fort Washington, PA (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5072715 Thu, 28 Jul 2011 06:42:05 +0100 5072715 http://www.medworm.com/index.php?rid=5516886&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FDePuy-Opens-Institute-for-Advanced-Education-and-Research-In-Orthopaedic-and-Neurological-Care-In-India Chennai, India (July 27, 2011) - DePuy, a Johnson & Johnson Company and one of the world's largest orthopaedic and neuroscience device companies, announced today the opening of the DePuy Institute for Advanced Education and Research in India..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5516886 Wed, 27 Jul 2011 15:01:25 +0100 5516886 http://www.medworm.com/index.php?rid=5516887&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FSurvey-Finds-More-Than-1-In-3-Americans-Have-Been-Personally-Affected-By-Infections-Resulting-From-A-Hospital-Stay IRVINE, CA (July 26, 2011): Survey results released today reveal that 34 percent of Americans[i] (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5516887 Wed, 27 Jul 2011 13:26:12 +0100 5516887 http://www.medworm.com/index.php?rid=5065577&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FThe-Amazing%2520Nurses-Contest-Celebrating-Americas-Caregivers New Brunswick, NJ – Monday, July 25, 2011 - The Johnson & Johnson Campaign for Nursing’s Future, as part of its ongoing campaign to support nurses and nursing education, is honored to sponsor the “Amazing Nurses” national contest to celebrate and reward the important role that these valued caretakers play in our communitie..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5065577 Tue, 26 Jul 2011 07:25:45 +0100 5065577 http://www.medworm.com/index.php?rid=5058980&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FTelaprevir-Receives-Positive-Opinion-From-The-Committee-For-Medicinal-Products-For-Human-Use-Chmp-For-The-Treatment-Of-Genotype-1-Hepatitis-C%2520Virus-HCV Beerse, Belgium, [July 22, 2011] (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5058980 Fri, 22 Jul 2011 16:21:53 +0100 5058980 http://www.medworm.com/index.php?rid=5058981&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FZytiga-Receives-Positive-Regulatory-Recommendation-In-The-European-Union-For-Treatment-Of-Metastatic-Castration-Resistant-Prostate-Cancer Beerse, Belgium, [22nd July 2011] (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5058981 Fri, 22 Jul 2011 13:44:04 +0100 5058981 http://www.medworm.com/index.php?rid=5058982&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FOrtho-Clinical-Diagnostics-Launches-Vitros-4600-Chemistry-System-For-Mid-To-High-Volume-Laboratories RARITAN, N.J. (July 22, 2011) — Ortho Clinical Diagnostics (OCD) today announced the launch of the VITROS® 4600 Chemistry System, a state-of-the-art analyzer that delivers high-quality, reliable test results for mid- to high-volume laboratories using the same core technologies that drive reliability and efficiency throughout OCD’s portfolio of products. The new analyzer completes the VITROS® x600 Family of Systems, which includes the VITROS® 5600 Integrated System and the VITROS® 3600 Immunodiagnostic System.  This portfolio of integrated instruments and broad, world-class menu of assays enable laboratories to deliver diagnostic results that help raise the standard of patient care in their institutions and networks..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5058982 Fri, 22 Jul 2011 13:04:29 +0100 5058982 http://www.medworm.com/index.php?rid=5058979&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FFDA-Issues-Complete-Response-Letter-to-Janssen-Biotech-Inc-for-SIMPONI-Supplemental-Biologic-License-Application Horsham, PA (July 22, 2011) – Janssen Biotech, Inc. announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response letter for its supplemental Biologics License Application (sBLA) for SIMPONI® (golimumab).  The application, filed in September 2010, seeks to expand the SIMPONI® physician label to include inhibiting the progression of structural damage, inducing major clinical response (MCR) and maintenance of reduction of signs and symptoms and maintenance of improved physical function in the treatment of moderately to severely active rheumatoid arthritis (RA). &#160..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5058979 Fri, 22 Jul 2011 10:37:15 +0100 5058979 http://www.medworm.com/index.php?rid=5516888&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FJanssen-Therapeutics-Teams-Up-With-Celebrity-Designer-David-Bromstad-To-Encourage-HIV-Testing [July 20, 2011, Titusville, NJ] – In an effort to elevate public awareness about the importance of HIV testing, Janssen Therapeutics, Division of Janssen Products, LP, is teaming up with David Bromstad*, host of HGTV’s Color Splash (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5516888 Thu, 21 Jul 2011 16:26:39 +0100 5516888 http://www.medworm.com/index.php?rid=5058983&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FFDA-Advisory-Committee-Recommends-Approval-Of-Remicade-For-Treatment-Of-Pediatric-Ulcerative-Colitis HORSHAM, PA, July 21, 2011 – Janssen Biotech, Inc., formerly Centocor Ortho Biotech Inc., announced today that the Gastrointestinal Drugs Advisory Committee (GIDAC) of the U.S. Food and Drug Administration (FDA) recommended the approval of REMICADE® (infliximab) for the treatment of moderately to severely active ulcerative colitis (UC) in pediatric patients who have had an inadequate response to conventional therapy.  REMICADE® was designated orphan drug status by the FDA on November 12, 2003 for the treatment of pediatric UC, and the supplemental Biologics License Application (sBLA) received priority review following its submission (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5058983 Thu, 21 Jul 2011 09:27:53 +0100 5058983 http://www.medworm.com/index.php?rid=5516889&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FEdurant-96-Week-Phase-3-Safety-And-Efficacy-Data-Presented-At-International-Aids-Society-Conference July 19, 2011, Titusville, NJ – Janssen Therapeutics, Division of Janssen Products, LP, presented today 96-week findings from two pivotal Phase 3 clinical trials, known as ECHO and THRIVE, comparing the efficacy, safety and virology profile of its non-nucleoside reverse transcriptase inhibitor (NNRTI) EDURANT™ (rilpivirine) tablets versus efavirenz (EFV) in antiretroviral treatment-naïve, HIV-1-infected adults. The pooled analysis at 96 weeks showed that 78 percent of patients achieved and sustained an undetectable plasma viral load (HIV-1 RNA less than 50 copies/mL) while taking EDURANT as part of combination therapy. These findings were presented today at the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Rome, Italy..... (Source: Johnson ... Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5516889 Tue, 19 Jul 2011 15:05:14 +0100 5516889 http://www.medworm.com/index.php?rid=5516890&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FJohnson-and-Johnson-Reports-2011-Second-Quarter-Results New Brunswick, NJ (July 19, 2011) – Johnson & Johnson today announced sales of $16.6 billion for the second quarter of 2011, an increase of 8.3% as compared to the second quarter of 2010.  Operational results increased 2.6% and the positive impact of currency was 5.7%.  Domestic sales increased 0.1%, while international sales increased 15.9%, reflecting operational growth of 4.9% and a positive currency impact of 11.0%..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5516890 Tue, 19 Jul 2011 10:55:53 +0100 5516890 http://www.medworm.com/index.php?rid=5516891&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FJohnson-and-Johnson-Announces-Third-Quarter-2011-Quarterly-Dividend New Brunswick, NJ (July 18, 2011) – Johnson & Johnson today announced that its Board of Directors has declared a cash dividend for the third quarter of 2011 of $0.57 per share on the company’s common stock.  The dividend is payable on Sept. 13, 2011, to shareholders of record at the close of business on Aug. 30, 2011. The ex-dividend date is Aug. 26, 2011..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5516891 Mon, 18 Jul 2011 07:22:10 +0100 5516891 http://www.medworm.com/index.php?rid=5032421&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FJanssen-Pharmaceuticals-Inc-Announces-Definitive-Agreement-To-Divest-Ortho-Dermatologics-Division TITUSVILLE, N.J., July 15, 2011 - Janssen Pharmaceuticals, Inc. today announced a definitive agreement to divest the assets of its Ortho Dermatologics division in the U.S. to subsidiaries of Valeant Pharmaceuticals International, Inc. for approximately $345 million in cash. The divestiture of Ortho Dermatologics’ assets includes prescription brands (RETIN-A MICRO®, ERTACZO® and RENOVA®) sold in the U.S. &#160..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5032421 Fri, 15 Jul 2011 13:19:10 +0100 5032421 http://www.medworm.com/index.php?rid=5032423&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FJohnson-Johnson-Launches-Healthy-Future-2015-Its-Citizenship-And-Sustainability-Goals New Brunswick, N.J. (July 14, 2011) – As 2011 marks the 125th (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5032423 Thu, 14 Jul 2011 14:57:24 +0100 5032423 http://www.medworm.com/index.php?rid=5032424&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FCilag-Gmbh-International-Completes-Acquisition-Of-Over-The-Counter-Brands-Of-J-B-Chemicals-Pharmaceuticals-Limited Zug, Switzerland, July 14, 2011 – Cilag GmbH International today announced the completion of the acquisition of the over-the-counter (OTC) brands of J B Chemicals & Pharmaceuticals Limited for the equivalent of approximately U.S. $245 million in cash. The brands included in the acquisition are RINZA®, Russia’s leading multi-symptom cough and cold brand, and DOKTOR MOM®, Russia’s number two selling cough brand, as well as several other brands. Johnson & Johnson LLC and its affiliates will market these products in Russia, the world's eighth largest OTC market, and in the Commonwealth of Independent States and other countries.  Cilag GmbH International and Johnson & Johnson LLC are wholly-owned subsidiaries of Johnson & Johnson..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5032424 Thu, 14 Jul 2011 13:28:21 +0100 5032424 http://www.medworm.com/index.php?rid=5032422&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FBiosense-Webster-Enrolls-First-Patient-In-Groundbreaking-SMART-AF-Trial-And-Completes-First-Atrial-Fibrillation-Ablation-Case-In-The-United-States Diamond Bar, CA – July 14th, 2011 – Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, announced the enrollment of the first patient in their latest groundbreaking clinical trial, the SMART-AF Investigational Device Exemption (IDE) study, and the treatment of the first patient with the new ThermoCool® SmartTouch™ Contact Force Sensing Catheter and Software Module in the United States..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5032422 Thu, 14 Jul 2011 08:45:56 +0100 5032422 http://www.medworm.com/index.php?rid=5013003&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FJohnson-and-Johnson-to-Host-Analyst-Conference-Call-on-Second-Quarter-Results-2011 New Brunswick, NJ (July 12, 2011) - Johnson & Johnson will host a conference call for financial analysts at 8:30 a.m. (Eastern Time) on Tuesday, July 19, 2011, to review second-quarter results.  Dominic Caruso, Vice President, Finance and Chief Financial Officer, Alex Gorsky, Vice Chairman, Executive Committee, Office of the Chairman, and Louise Mehrotra, Vice President, Investor Relations, will host the call..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5013003 Tue, 12 Jul 2011 13:10:51 +0100 5013003 http://www.medworm.com/index.php?rid=5013004&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FCrucell-Discovers-Important-New-Antibody-Against-Influenza-A Leiden, The Netherlands (July 7, 2011) – Dutch biopharmaceutical company Crucell N.V. and The Scripps Research Institute today published an article in the world’s leading journal of original scientific research Science (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5013004 Fri, 08 Jul 2011 13:20:16 +0100 5013004 http://www.medworm.com/index.php?rid=5013005&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FJohnson-and-Johnson-Announces-Global-Sponsorship-Of-The-2014-FIFA-World-Cup-Brazil Sao Paulo, Brazil and New Brunswick, NJ (July 7, 2011) – Johnson & Johnson today announced that the company has entered into an agreement to become a global sponsor of the 2014 FIFA World Cup Brazil™, becoming the eighth and final FIFA World Cup™ Sponsor..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5013005 Thu, 07 Jul 2011 14:11:17 +0100 5013005 http://www.medworm.com/index.php?rid=5013006&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FJanssen-Pharmaceutica-NV-Completes-Divestiture-Of-Animal-Health-Business-To-Elanco-A-Division-Of-Eli-Lilly-And-Company Beerse, Belgium (July 7, 2010) – (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5013006 Thu, 07 Jul 2011 13:21:22 +0100 5013006 http://www.medworm.com/index.php?rid=5516892&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FFDA-Approves-XARELTO-rivaroxaban-tablets-to-Help-Prevent-Deep-Vein-Thrombosis-in-Patients-Undergoing-Knee-or-Hip-Replacement-Surgery Raritan, NJ (July 1, 2011) — Janssen Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved XARELTO® (rivaroxaban tablets), a novel, once-daily, oral anticoagulant for the prevention (prophylaxis) of deep vein thrombosis (DVT) which may lead to a pulmonary embolism (PE) in people undergoing knee or hip replacement surgery..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5516892 Fri, 01 Jul 2011 08:10:59 +0100 5516892 http://www.medworm.com/index.php?rid=4988328&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FFDA-Approves-XARELTO-rivaroxaban-tablets-to-Help-Prevent-Deep-Vein-Thrombosis-in-Patients-Undergoing-Knee-or-Hip-Replacement-Surgery Raritan, NJ (July 1, 2011) — Janssen Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved XARELTO® (rivaroxaban tablets), a novel, once-daily, oral anticoagulant for the prevention (prophylaxis) of deep vein thrombosis (DVT) which may lead to a pulmonary embolism (PE) in people undergoing knee or hip replacement surgery..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4988328 Fri, 01 Jul 2011 08:10:59 +0100 4988328 http://www.medworm.com/index.php?rid=4979216&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FDr-Napoleone-Ferrara-Wins-2011-Dr-Paul-Janssen-Award-for-Biomedical-Research Washington, DC (June 28, 2011) – Johnson & Johnson today announced the winner of the 2011 Dr. Paul Janssen Award for Biomedical Research during the BIO International Convention (BIO) in Washington D.C.  Napoleone Ferrara, M.D., is the seventh leading scientist to win the Award, which honors a scientist or team of scientists whose contributions have the potential to significantly improve the health and lives of people around the world.  Dr. Ferrara was selected by an independent committee of eight renowned scientists, including Nobel Laureates, Lasker Prize winners, and others, for his research on angiogenesis, the process of new blood vessel formation that plays a key role in cancer proliferation and a number of other diseases.  Dr. Ferrara’s discoveries opened the d... Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4979216 Wed, 29 Jun 2011 12:47:08 +0100 4979216 http://www.medworm.com/index.php?rid=4979218&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FTibotec-Pharmaceuticals%2520-Announces%2520-Agreement%2520-With-Gilead-Sciences-To%2520-Develop-And-Commercialize-A-New-Fixed-Dose-Combination-Of%2520-Prezista-And-Cobicistat CORK, Ireland, 28 June , 2011 – (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4979218 Tue, 28 Jun 2011 12:54:43 +0100 4979218 http://www.medworm.com/index.php?rid=4979217&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FMcNEIL-Consumer-Healthcare-Announces-Voluntary-Recall-Of-One-Product-Lot-Of-TYLENOL-Extra-Strength-Caplets-225-Count Fort Washington, PA (June 28, 2011) – McNeil Consumer Healthcare, Division of McNEIL-PPC, Inc., is recalling at the retail level one product lot (60,912 bottles) of TYLENOL®, Extra Strength Caplets, 225 count bottles, distributed in the U.S.  The recalled product was manufactured in February, 2009. McNeil is taking this action following a small number of odor reports, including musty, moldy odor. The uncharacteristic musty, moldy odor has been linked to the presence of trace amounts of a chemical known as 2,4,6-tribromoanisole (TBA).   &#160..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4979217 Tue, 28 Jun 2011 09:50:18 +0100 4979217 http://www.medworm.com/index.php?rid=4979219&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FASP-Launches-GLOSAIR-Healthcare-Environmental-Decontamination-at-The-2011-APIC-Conference-To-Protect-Against-The-Risk-Of-Deadly-Infections-In-Healthcare-Facilities Irvine, CA (June 27, 2011): Advanced Sterilization Products (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4979219 Mon, 27 Jun 2011 11:08:52 +0100 4979219 http://www.medworm.com/index.php?rid=4963705&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FJanssen-Products-LP-Modifies-Prescribing-Information-For-PROCRIT-Epoetin-alfa-In-Chronic-Kidney-Disease Horsham, PA, (June 24, 2011) (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4963705 Fri, 24 Jun 2011 05:38:55 +0100 4963705 http://www.medworm.com/index.php?rid=4956416&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FJohnson-Johnson-Medical-Companies-Opens-Innovation-Center-In-China Suzhou, China (June 22, 2011) --- Johnson & Johnson Medical (Suzhou) Ltd announced today it has established an innovation center in China to design and develop medical devices and diagnostic products specifically for Asia’s emerging markets, primarily focusing on China and India. The Johnson & Johnson Medical Companies Asia Pacific Innovation Center located in Suzhou, China was officially opened today by Alex Gorsky, Vice Chairman of the Executive Committee, Johnson & Johnson..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4956416 Wed, 22 Jun 2011 15:27:07 +0100 4956416 http://www.medworm.com/index.php?rid=4956415&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FTibotec-Therapeutics-Becomes-Janssen-Therapeutics-Part-Of-The-Janssen-Pharmaceutical-Companies Titusville, NJ, June 22, 2011 – Tibotec Therapeutics, Division of Centocor Ortho Biotech Products, L.P. announced that it has changed its name to Janssen Therapeutics, Division of Janssen Products, LP.  The change, effective immediately, is part of the global adoption of a common identity for all Janssen Pharmaceutical Companies to provide even greater collaboration, value and treatment innovation for individuals living with serious medical conditions, including HIV/AIDS and hepatitis C..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4956415 Wed, 22 Jun 2011 08:21:29 +0100 4956415 http://www.medworm.com/index.php?rid=4940798&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FOrtho-McNeil-Janssen-Pharmaceuticals-Inc-Voluntarily-Recalls-One-Lot-of-RISPERDAL-Tablets-and-One-Lot-of-Risperidone-Tablets Titusville, NJ (June 17, 2011) – Ortho-McNeil-Janssen Pharmaceuticals, Inc. is initiating a voluntary recall of one lot of RISPERDAL® (risperidone) 3mg Tablets, marketed by Janssen Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. and one lot of risperidone 2mg Tablets, marketed by Patriot Pharmaceuticals, LLC, a wholly owned subsidiary of Ortho-McNeil-Janssen Pharmaceuticals, Inc.  The recalls stem from two consumer reports of an uncharacteristic odor thought to be caused by trace amounts of TBA (2,4,6 tribromoanisole).  &#160..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4940798 Fri, 17 Jun 2011 06:02:54 +0100 4940798 http://www.medworm.com/index.php?rid=4940799&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FEthicon-Endo-Surgery-Launches-ENSEAL-G2-Super-Jaw-First-Bi-Polar-Advanced-Energy-Technology-Designed-To-Improve-Surgeon-Confidence-In-Tissue-Affect Cincinnati, OH – (June 15, 2011)– To address surgeons’ need for achieving strong vessel seals while remaining gentle on tissue in open surgery, Ethicon Endo-Surgery, Inc. (EES) today announces the launch of its innovative ENSEAL® G2 Super Jaw advanced bipolar technology.  The new technology is designed with proprietary I-BLADE® technology to deliver high uniform compression for sealing vessels consistently along the length of the 40mm curved jaw. Other bipolar devices rely solely on the force of initial jaw closure to provide compression – which results in a fall-off in force from the proximal to the distal end of the jaws and may lead to bleeding at the tip of the jaw. ENSEAL® G2 Super Jaw is designed for open surgical procedures such as colorectal, gynecological and gener... Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4940799 Wed, 15 Jun 2011 14:17:59 +0100 4940799 http://www.medworm.com/index.php?rid=4940800&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FEthicon-Endo-Surgery-Introduces-Innovative-New-Generator-to-Help-Simplify-Use-of-Advanced-Energy-Technology-in-the-OR Cincinnati, OH (June 15, 2011) – In an effort to help simplify the OR, Ethicon Endo-Surgery, Inc. (EES) today announces U.S. FDA 510(k) clearance and the launch of the first ever Advanced Energy Generator made to power both ultrasonic and advance bipolar technologies and designed for easy set set-up and use in the operating room..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4940800 Wed, 15 Jun 2011 14:08:25 +0100 4940800 http://www.medworm.com/index.php?rid=4940801&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FACUVUE-Brand-Contact-Lenses-Launches-Healthy%2520Vision-With-Dr-Val-Jones JACKSONVILLE, Fla. (June 15, 2011) – VISTAKON®, Division of Johnson & Johnson Vision Care, Inc., today announced the launch of Healthy Vision™ with Dr. Val Jones (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4940801 Wed, 15 Jun 2011 12:48:28 +0100 4940801 http://www.medworm.com/index.php?rid=4940802&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2Fjohnson-and-johnson-announces-special-charge-related-to-restructuring-plans-for-cordis-corporation-subsidiary (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4940802 Wed, 15 Jun 2011 12:28:46 +0100 4940802 http://www.medworm.com/index.php?rid=4940803&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2Fcordis-announces-discontinuation-of-nevo-sirolimus-eluting-coronary-stent Bridgewater, NJ (June 15, 2011) -- Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, today announced it will no longer pursue the development of the NEVO™ Sirolimus-Eluting Coronary Stent in order to focus on other cardiovascular therapies where significant patient need exists. The company will also stop the manufacture of CYPHER® and CYPHER SELECT® Plus Sirolimus-Eluting Coronary Stents by the end of 2011..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4940803 Wed, 15 Jun 2011 12:18:27 +0100 4940803 http://www.medworm.com/index.php?rid=4925827&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FFormer-Chairman-and-CEO-of-Aetna-Inc-Ronald-Williams-Appointed-to-Johnson-and-Johnson-Board-of-Directors New Brunswick, N.J. (June 14, 2011) – Ronald A. Williams, former chairman and chief executive officer (CEO) of Aetna Inc., has been appointed to the Board of Directors of Johnson & Johnson (JNJ: NYSE), the world’s most comprehensive and broadly based health care products company.  Mr. Williams will serve on the Compensation & Benefits Committee and the Public Policy Advisory Committee of the Board..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4925827 Tue, 14 Jun 2011 13:21:41 +0100 4925827 http://www.medworm.com/index.php?rid=4925828&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FEthicon-Endo-Surgery-to-Showcase-Broadest-Spectrum-of-Innovative-Bariatric-Surgical-Options-Physician-Best-Practices-and-Mobile-Web-Based-After-Care-Patient-Programs-At-ASMBS Cincinnati, OH (June 10, 2011) – To address the need for more efficient and cost-effective bariatric surgical options to treat a variety of patient needs, Ethicon Endo-Surgery (EES), a global leader in surgical innovations, will showcase the broadest spectrum of bariatric surgical solutions and innovative technologies during the American Society for Metabolic and Bariatric Surgery (ASMBS) 28th Annual Meeting at the Gaylord Hotel and Convention Center in Orlando, Florida, June 12-17, 2011.  EES will also highlight the latest metabolic research and a new mobile and web-based post-operation patient care support tool, and provide access to physician best practices..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4925828 Fri, 10 Jun 2011 08:02:57 +0100 4925828 http://www.medworm.com/index.php?rid=4925829&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FCodman-Neurovascular-Launches-ORBIT-GALAXY-Detachable-Coil-System Raynham, MA (JUNE 8, 2011) – (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4925829 Thu, 09 Jun 2011 08:01:29 +0100 4925829 http://www.medworm.com/index.php?rid=4925830&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FDACOGEN-decitabine-showed-an-overall-survival-advantage-compared-with-the-accepted-standard-therapies-in-older-patients Chicago/US, Beerse/Belgium (June 6th 2011) (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4925830 Tue, 07 Jun 2011 14:35:36 +0100 4925830 http://www.medworm.com/index.php?rid=4897633&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FLate-Breaking-ASCO-Data-Demonstrate-Circulating-Tumor-Cells-As-Potential-Biomarker-for-Metastatic-Prostate-Cancer-Clinical-Trials This study represents the first randomized, double-blind, placebo controlled Phase III trial to evaluate CTCs as a potential biomarker for overall survival.  Biomarkers are of scientific interest as, if validated, they could be used as a surrogate for a clinical endpoint and may help accelerate the clinical trial process..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4897633 Sat, 04 Jun 2011 09:04:11 +0100 4897633 http://www.medworm.com/index.php?rid=4897634&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FZYTIGA-Data-to-be-Presented-at-2011-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting Chicago, IL (June 3, 2011) – Data related to ZYTIGA™ (abiraterone acetate) will be presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.  The studies were sponsored by Ortho Biotech Oncology Research & Development, unit of Cougar Biotechnology, Inc..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4897634 Fri, 03 Jun 2011 15:29:45 +0100 4897634 http://www.medworm.com/index.php?rid=4887973&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FAnimas-Vibe-the-First-Integrated-Offering-from-Animas-Corporation-and-Dexcom-Inc-Receives-European-CE-Mark-Approval West Chester, PA. (June 2, 2011) – Animas Corporation (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4887973 Thu, 02 Jun 2011 05:59:29 +0100 4887973 http://www.medworm.com/index.php?rid=4887974&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FReport-Finds-Americans-More-Concerned-About-Germs-on-Their-Hands-Their-Shopping-Carts-than-Germs-in-Their-Mouths Morris Plains, NJ (June 1, 2011) – You might think that in an increasingly germ-o-phobic nation, people would take extra care to eliminate oral disease-causing germs from their mouths, but you’d be wrong.  While nearly 80 percent of Americans feel concerned about germs on their hands, only 66 percent worry about germs in their mouths, according to the new “Healthy Mouths” report from the makers of LISTERINE® Antiseptic and REACH® brand..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4887974 Wed, 01 Jun 2011 07:17:49 +0100 4887974 http://www.medworm.com/index.php?rid=4867160&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FJohnson-and-Johnson-Highlights-Strategies-for-Growth-Through-Differentiated-Medicines-Transformational-Pipeline-and-Global-Product-Launches New Brunswick, N.J. (May 26, 2011) – Johnson & Johnson will review growth strategies for its Pharmaceuticals business at a meeting with the investment community today.  Senior leaders from the company’s executive committee and pharmaceuticals segment will review how the business plans to address some of the world’s major unmet medical needs and outpace pharmaceutical market growth with an optimized product portfolio, robust pipeline and a demonstrated track record of successful global product launches..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4867160 Thu, 26 May 2011 11:07:36 +0100 4867160 http://www.medworm.com/index.php?rid=4867162&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FNew-Four-Year-STELARA-Data-Show-Consistent-Safety-Profile-Over-Time-In-Patients-With-Moderate-To-Severe-Plaque-Psoriasis Toronto, CA (May 25, 2011) – New findings presented today from pooled analyses of the STELARA™ (ustekinumab) psoriasis clinical development program showed that the safety profile of STELARA™ and rates of adverse events remained consistent and stable over time in adults with moderate to severe plaque psoriasis receiving up to four years of treatment.  Investigators also reported findings from an analysis of four placebo-controlled Phase 3 trials across patient populations on three continents and found that the efficacy and safety of STELARA™ in patients of Japanese and Korean-Taiwanese descent were consistent with findings previously reported in North American and European populations.   (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4867162 Wed, 25 May 2011 13:00:08 +0100 4867162 http://www.medworm.com/index.php?rid=4867163&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FInterleukin-6-Inhibitor-Sirukumab-CNTO-136-Phase-2-Data-Show-Promise-In-The-Treatment-Of-Active-Rheumatoid-Arthritis London, England, (May 25, 2011) – Results from a Phase 2 multicenter, randomized, double-blind, proof-of-concept and dose-finding study showed that treatment with sirukumab (CNTO 136) improved signs and symptoms of rheumatoid arthritis (RA) in patients with active disease despite treatment with methotrexate (MTX).  Findings from Part A of the two-part trial presented at the 2011 European League Against Rheumatism (EULAR) Congress showed that a greater proportion of patients receiving sirukumab achieved a significantly greater reduction in Disease Activity Score 28 (DAS28 CRP) at week 12, the primary endpoint of the study.  All patients in this study were continued on MTX.  Sirukumab is a human monoclonal IgG1 (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4867163 Wed, 25 May 2011 12:43:59 +0100 4867163 http://www.medworm.com/index.php?rid=4867161&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FPhase-3-Study-Published-in-The-New-England-Journal-of-Medicine-Finds-Survival-of-Patients-with-Metastatic-Castration-Resistant-Prostate-Cancer-is-Improved-with-ZYTIGA Horsham, PA (May 25, 2011) – A study titled “Abiraterone and Increased Survival in Metastatic Prostate Cancer,” published in the May 26 issue of NEJM, (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4867161 Wed, 25 May 2011 10:07:09 +0100 4867161 http://www.medworm.com/index.php?rid=4867165&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FACUVUE-Brand-Contact-Lenses-Launches-Celebrity-Mentorship-Contest-With-Joe-Jonas-Meaghan-Martin-Charice-Allyson-Felix-and-Sterling-Knight Jacksonville, FL (May 24, 2011) – VISTAKON®, Division of Johnson & Johnson Vision Care, Inc., and makers of ACUVUE® Brand Contact Lenses, today announced the “ACUVUE® 1•DAY (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4867165 Tue, 24 May 2011 15:16:38 +0100 4867165 http://www.medworm.com/index.php?rid=4867164&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FVeridex-Launches-CELLTRACKS-Circulating-Melanoma-Cell-Kit-For-Research-Use Raritan, NJ (May 24, 2011) – Veridex, LLC today announced the launch of the CELLTRACKS® Circulating Melanoma Cell (CMC) kit, providing research scientists with a fast, convenient and reliable way to capture CMCs for research studies. Using proprietary immunomagnetic technology to capture and count CMCs, the CELLTRACKS® CMC kit is designed to offer data that support researchers engineering investigational therapies that are based on a specific protein or mutation..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4867164 Tue, 24 May 2011 08:23:20 +0100 4867164 http://www.medworm.com/index.php?rid=4867166&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FCilag-GmbH-International-Announces-Definitive-Agreements-to-Acquire-The-Over-The-Counter-Brands-of-J-B-Chemicals-and-Pharmaceuticals-Limited Zug, Switzerland (May 23, 2011) - Cilag GmbH International today announced definitive agreements to acquire the over-the-counter (OTC) brands of J B Chemicals & Pharmaceuticals Limited for the equivalent of approximately U.S. $260 million in cash. The brands included in the acquisition are RINZA®, Russia’s leading multi-symptom cough and cold brand, and DOKTOR MOM®, Russia’s number two selling cough brand, as well as several other brands. Johnson & Johnson LLC and its affiliates will market these products in Russia, the world's eighth largest OTC market, and in the Commonwealth of Independent States and other countries. Cilag GmbH International and Johnson & Johnson LLC are wholly-owned subsidiaries of Johnson & Johnson..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4867166 Mon, 23 May 2011 15:20:28 +0100 4867166 http://www.medworm.com/index.php?rid=4844553&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FCORDIS-Receives-FDA-Approval-for-EXOSEAL-Vascular-Closure-Device Bridgewater, NJ (May 20, 2011) -- Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, today announced the approval of the EXOSEAL™ Vascular Closure Device in the US.   EXOSEAL™ incorporates a number of new advances in technology and simplicity of design to provide precise and secure extravascular arterial closure..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4844553 Fri, 20 May 2011 14:54:42 +0100 4844553 http://www.medworm.com/index.php?rid=4844552&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FFDA-Approves-EDURANT-rilpivirine-For-Use-in-Treatment-Naive-Adults-with-HIV-1 Titusville, NJ, May 20, 2011 – The US Food and Drug Administration (FDA) today approved EDURANTTM (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4844552 Fri, 20 May 2011 07:56:30 +0100 4844552 http://www.medworm.com/index.php?rid=4844554&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FJohnson-and-Johnson-to-Host-Pharmaceuticals-Business-Review New Brunswick, NJ (May 19, 2011) – Johnson & Johnson (NYSE: JNJ) will host a review of its Pharmaceuticals business for the investment community beginning at 9:00 a.m. (Eastern Time) on Thursday, May 26, 2011 at The Heldrich Hotel, in New Brunswick, N.J. ending at approximately 3:00 p.m..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4844554 Thu, 19 May 2011 06:04:47 +0100 4844554 http://www.medworm.com/index.php?rid=4835266&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FSchizophrenia24x7-com-A-New-Interactive-Website-for-Patients-and-Carers >To view a short video about Schizophrenia 24x7 please visit http://www.brainshark.com/janssencns/Schizophrenia24x7 (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4835266 Wed, 18 May 2011 12:25:51 +0100 4835266 http://www.medworm.com/index.php?rid=4835268&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FCelebrity-Kristin-Chenoweth-Lends-Her-Voice-to-New-LISTERINE-WHITENING-Campaign Morris Plains, NJ (May 16, 2011) –  (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4835268 Mon, 16 May 2011 16:15:21 +0100 4835268 http://www.medworm.com/index.php?rid=5516893&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FCordis-Launching-Two-New-Products-at-EuroPCR-Congress (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5516893 Mon, 16 May 2011 15:55:22 +0100 5516893 http://www.medworm.com/index.php?rid=5516894&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FCordis-Launches-Integrated-Solutions-for-Transradial-Care (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=5516894 Mon, 16 May 2011 15:51:30 +0100 5516894 http://www.medworm.com/index.php?rid=4835267&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FNew-SPLENDA-ESSENTIALS-No-Calorie-Sweetener-Products-Give-Consumers-Added-Boost-of%2520B-Vitamins-Antioxidants-or-Fiber Fort Washington, PA (May 16, 2011) – (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4835267 Mon, 16 May 2011 08:38:45 +0100 4835267 http://www.medworm.com/index.php?rid=4823896&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FEthicon-Endo-Surgery-Partners-With-Colorectal-Surgeons-and-Community-at-ASCRS-to-Improve-Patient-Outcomes Cincinnati, OH (May 13, 2011) – Ethicon Endo-Surgery (EES) will feature its comprehensive portfolio of colorectal solutions and physician-led educational programs, aimed to advance surgical skills in both open and minimally invasive colorectal procedures to promote better patient outcomes, during the American Society of Colon & Rectal Surgeons (ASCRS) Annual Scientific meeting, May 14-18 in Vancouver, Canada. &#160..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4823896 Sat, 14 May 2011 05:31:46 +0100 4823896 http://www.medworm.com/index.php?rid=4808322&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FJanssen-Identifies-Trace-Amounts-of-TBA-in-5-Batches-of-PREZISTA-darunavir-in-the-EU-and-Canada High Wycombe, UK – (May 11 2011) – Janssen-Cilag International N.V. today announced the company is working with regulatory authorities in five countries to address trace amounts of  TBA (2,4,6 tribromoanisole) identified in five batches of the HIV/AIDS medicine PREZISTA® (darunavir).  The countries affected include the United Kingdom, Ireland, Germany, Austria and Canada.   &#160..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4808322 Wed, 11 May 2011 12:13:40 +0100 4808322 http://www.medworm.com/index.php?rid=4808323&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FContact-Lens-Wearers-Are-Significantly-Non-Compliant-Before-During-and-After-Contact-Lens-Wear-Studies-Show Jacksonville, FL (May 11, 2011) – Contact lens wearers are significantly non-compliant in virtually all the active steps involved in soft contact lens wear, including hand washing, case hygiene, lens disinfection and following the recommended lens replacement schedule, according to new data on patient attitudes and behaviors regarding compliance with soft contact lenses..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4808323 Wed, 11 May 2011 11:28:39 +0100 4808323 http://www.medworm.com/index.php?rid=4808321&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FAnimas-and-LifeScan-Strengthen-Strategic-Focus-to-Better-Serve-People-Living-with-Diabetes West Chester, PA (May 11, 2011) – Animas Corporation and LifeScan, Inc., both members of the Johnson & Johnson Family of Diabetes Companies, today announced plans to further build upon their existing collaborative efforts to co-develop and market innovative new products and tools for people living with diabetes.  The increased collaboration also will include more closely aligning their commercial organizations to actively co-promote their product offerings, such as the OneTouch® Ping® Glucose Management System. Animas and LifeScan will work closely to bring people with diabetes and their healthcare professionals the tools they need to better manage a disease that affects more than 285 million people across the globe..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4808321 Wed, 11 May 2011 08:10:37 +0100 4808321 http://www.medworm.com/index.php?rid=4808325&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FAlzheimers-Association-Salutes-Advocate-and-Mountaineer-Now-Climbing-Everest-as-Part-of-The-7-Summits-Climb-for-Alzheimers South San Francisco, CA (May 10, 2011) (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4808325 Tue, 10 May 2011 13:38:30 +0100 4808325 http://www.medworm.com/index.php?rid=4808324&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FNew-Phase-3-Study-Results-Show-REMICADE-is-Effective-in-the-Treatment-of-Pediatric-Patients-With-Moderate-to-Severe-Ulcerative-Colitis >Chicago, IL (May 9, 2011) -- Data from a Phase 3 randomized, multicenter, open-label study demonstrated clinical response with REMICADE® (infliximab) in the treatment of pediatric patients with moderately to severely active ulcerative colitis (UC), and showed a safety profile consistent with previous clinical trials conducted in an adult population.  The pediatric UC findings, presented today at Digestive Disease Week, showed REMICADE induced clinical response in 73 percent of patients aged 6-17 years at week 8, the primary endpoint of the trial.  REMICADE received U.S. Food and Drug Administration (FDA) approval for the treatment of adults with moderately to severely active UC in September 2005 and in October 2006, REMICADE received FDA approval for maintaining clinical remiss... Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4808324 Tue, 10 May 2011 05:11:23 +0100 4808324 http://www.medworm.com/index.php?rid=4799416&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FPhase-2b-Data-Show-Treatment-With-STELARA-Induced-and-Maintained-Clinical-Response-in-Patients-With-Moderate-to-Severe-Crohns-Disease >Chicago, IL (May 9, 2011) -- New study findings showed that treatment with STELARA® (ustekinumab) induced and maintained clinical response in patients with moderate to severe Crohn's disease who had previously failed or were intolerant to at least one tumor necrosis factor (TNF) antagonist.  Investigators presented findings from a Phase 2b study at Digestive Disease Week, which showed nearly 40 percent of patients receiving STELARA 6 mg/kg achieved clinical response, defined as a 100 point reduction in the Crohn's Disease Activity Index (CDAI), at week 6, the primary endpoint of the study.  Additionally, a significantly greater proportion of week 6 responders to STELARA continuing treatment with STELARA through week 22 were in clinical response and in clinical remission compare... Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4799416 Mon, 09 May 2011 14:16:31 +0100 4799416 http://www.medworm.com/index.php?rid=4799417&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FLifeScan-Fulfills-Exclusive-US-Agreement-With-Medtronic >Milpitas, CA (May 9, 2011) -- LifeScan, Inc., makers of the top-selling OneTouch® Brand of Blood Glucose Monitoring Systems for people with diabetes, has fulfilled the terms of its exclusive, three-year agreement to provide Medtronic customers in the U.S. with the OneTouch® UltraLink® Blood Glucose Meter that wirelessly transmits glucose values to Medtronic MiniMed Paradigm®insulin pumps and Guardian®REAL-Time continuous glucose monitoring (CGM) systems..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4799417 Mon, 09 May 2011 13:58:01 +0100 4799417 http://www.medworm.com/index.php?rid=4799418&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FLiving-with-Schizophrenia-Documentary-Shines-Spotlight-on-People-with-Schizophrenia-A-Misunderstood-and-Stigmatized-Illness Titusville, N.J. (May 9, 2011) – Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., proudly announces the world premiere of “Living with Schizophrenia: A Call for Hope and Recovery,” a half-hour documentary film that tells the story of three people who are living meaningful lives with schizophrenia, a chronic and potentially disabling brain disorder. The film sets out to increase understanding and to reduce the fear and stigma often associated with this mental health condition. About one percent of the US adult population and approximately 24 million people globally are living with schizophrenia..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4799418 Mon, 09 May 2011 12:51:51 +0100 4799418 http://www.medworm.com/index.php?rid=4791777&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FJOHNSONS-Launches-Campaign-to-Help-Ensure-Families-Across-the-Country-Can-Treasure-the-Joy-of-a-Healthy-Baby >Skillman, NJ (May 6, 2011) -- In honor of Mother's Day, the JOHNSON'S® Brand is launching the integrated campaign,TREASURING EVERYDAY JOY™ with JOHNSON'S®,kicking off with a celebrity driven exhibit, a charity initiative on Facebook and a documentary on WE tv – to benefit the MARCH OF DIMES®. Top talentAlyson Hannigan(CBS'sHow I Met Your Mother),Melissa Rycroft(TV Correspondent and ABC'sDancing with the Starsalum) and MARCH OF DIMES® ambassadorsJulie Bowen(ABC'sModern Family),Melissa Joan Hart(ABC Family'sMelissa & Joey)andKellie Martin(ERandLife Goes On) will share their footprints for an exclusive "Footprints" exhibit that symbolizes not only the 'joy' behind baby's first steps, but also the first step toward helping every family experience the joy of having a healthy baby, ... Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4791777 Fri, 06 May 2011 05:29:09 +0100 4791777 http://www.medworm.com/index.php?rid=4784863&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FBiosense-Webster-Announces-Agreement-to-Distribute-Stereotaxis-Odyssey-Product-Portfolio-Worldwide Diamond Bar, CA (May 5th, 2011) – Biosense Webster, Inc., the worldwide leader in the diagnosis and treatment of cardiac arrhythmias today announced the extension of their strategic collaboration with Stereotaxis, Inc..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4784863 Thu, 05 May 2011 15:17:30 +0100 4784863 http://www.medworm.com/index.php?rid=4784862&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FBiosense-Webster-Showcases-Cutting-Edge-Innovation-at-Heart-Rhythm-2011 >Diamond Bar, CA - (May 05, 2011)- Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, will showcase its portfolio of cutting edge innovative technologies at the 2011 Heart Rhythm Meeting. Heart Rhythm is the largest scientific meeting in the field of Electrophysiology and will be held in San Francisco, CA from May 4th – 7th, at the Moscone Center..... (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4784862 Thu, 05 May 2011 05:17:00 +0100 4784862 http://www.medworm.com/index.php?rid=4784864&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FJohnson-and-Johnson-to-Participate-in-Bank-of-America-Merrill-Lynch-2011-Health-Care-Conference New Brunswick, NJ (May 4, 2011) -- Johnson & Johnson (NYSE: JNJ) will participate in the Bank of America Merrill Lynch 2011 Health Care Conference on Tuesday, May 10th (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4784864 Wed, 04 May 2011 14:24:58 +0100 4784864 http://www.medworm.com/index.php?rid=4784865&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FAmericans-Arent-Taking-Proper-Care-to-Protect-Eyes-from-UV-Damage Jacksonville, FL (May 4, 2011) – Around the world, sight is valued as the most important of the five senses, along with a strong belief that good vision positively impacts quality of life.1 (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4784865 Wed, 04 May 2011 14:15:53 +0100 4784865 http://www.medworm.com/index.php?rid=4784866&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2FHarnessing-Mobile-Phone-Technology-to-Improve-Maternal-and-Child-Health-Mobile-Alliance-for-Maternal-Action-Partnership-Established >States News Service: May 3, 2011 (Source: Johnson and Johnson) Johnson and Johnson news http://www.medworm.com/rss/comments.php?id=4784866 Tue, 03 May 2011 15:01:37 +0100 4784866